Apply precautions for pain management in pheochromocytoma and paraganglioma
STEP 1 — Gather Information
Collect pain characteristics (location, severity, quality), assess for bone metastases via imaging or symptoms, review current medications (especially metoclopramide, antidepressants, dexamethasone), and evaluate palliative care needs. → Proceed to medication risk screening.
STEP 2 — Rule In / Rule Out
Is the patient taking any medication known to induce hypertensive crisis (e.g., metoclopramide, tricyclic antidepressants, SNRIs, MAO inhibitors, high-dose dexamethasone)? If yes, discontinue or avoid these agents; if no, proceed to analgesic selection.
STEP 3 — Classify or Stratify
Classify pain severity using WHO analgesic ladder (mild, moderate, severe) and assess for skeletal-related events (spinal cord compression, hypercalcemia, pathological fractures). → Determine analgesic step and need for adjuvant therapy or bone-directed treatment.
STEP 4 — Decide
Initiate multidisciplinary pain management with palliative care unit, select analgesics per WHO ladder avoiding high-risk agents, consider bone-modifying agents (e.g., zoledronic acid) or radiotherapy for bone metastases, and monitor for side effects and blood pressure.
Clinical Guardrails / Mimics / Pitfalls
Do not use metoclopramide for nausea/vomiting due to hypertensive crisis risk; avoid tricyclic antidepressants and SNRIs for neuropathic pain; avoid high-dose dexamethasone; use opioids with prophylactic laxatives to prevent constipation; avoid NSAIDs if renal impairment; ensure blood pressure monitoring during analgesic initiation.
Concrete Clinical Example
A 58-year-old patient with metastatic PPGL to lumbar spine reports worsening back pain (7/10) despite acetaminophen. Current meds include metoclopramide for nausea. Discontinue metoclopramide, start low-dose morphine with laxative, involve palliative care for opioid titration, add zoledronic acid for bone lesions, and coordinate radiotherapy if pain persists.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165